PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival
Published 2019 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
PI3K/mTOR inhibition of IDH1 mutant glioma leads to reduced 2HG production that is associated with increased survival
Authors
Keywords
-
Journal
Scientific Reports
Volume 9, Issue 1, Pages -
Publisher
Springer Science and Business Media LLC
Online
2019-07-19
DOI
10.1038/s41598-019-47021-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- 2-Hydroxyglutarate-Mediated Autophagy of the Endoplasmic Reticulum Leads to an Unusual Downregulation of Phospholipid Biosynthesis in Mutant IDH1 Gliomas
- (2018) Pavithra Viswanath et al. CANCER RESEARCH
- First-in human, phase 1, dose-escalation pharmacokinetic and pharmacodynamic study of the oral dual PI3K and mTORC1/2 inhibitor PQR309 in patients with advanced solid tumors (SAKK 67/13)
- (2018) Andreas Wicki et al. EUROPEAN JOURNAL OF CANCER
- Temozolomide-associated hypermutation in gliomas
- (2018) Serah Choi et al. NEURO-ONCOLOGY
- Parallel PI3K, AKT and mTOR inhibition is required to control feedback loops that limit tumor therapy
- (2018) Anuja Sathe et al. PLoS One
- Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate
- (2018) Ovidiu C. Andronesi et al. Nature Communications
- Voxtalisib (XL765) in patients with relapsed or refractory non-Hodgkin lymphoma or chronic lymphocytic leukaemia: an open-label, phase 2 trial
- (2018) Jennifer R Brown et al. Lancet Haematology
- Rapamycin (mTORC1 inhibitor) reduces the production of lactate and 2-hydroxyglutarate oncometabolites in IDH1 mutant fibrosarcoma cells
- (2017) Zoltán Hujber et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014
- (2017) Quinn T Ostrom et al. NEURO-ONCOLOGY
- Clonal expansion and epigenetic reprogramming following deletion or amplification of mutantIDH1
- (2017) Tali Mazor et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Induction of synthetic lethality in IDH1-mutated gliomas through inhibition of Bcl-xL
- (2017) Georg Karpel-Massler et al. Nature Communications
- Pediatric and adult glioblastoma radiosensitization induced by PI3K/mTOR inhibition causes early metabolic alterations detected by nuclear magnetic resonance spectroscopy
- (2017) Alice Agliano et al. Oncotarget
- Vertical inhibition of the PI3K/Akt/mTOR pathway is synergistic in breast cancer
- (2017) S-U Woo et al. Oncogenesis
- The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary
- (2016) David N. Louis et al. ACTA NEUROPATHOLOGICA
- The PI3K/AKT Pathway as a Target for Cancer Treatment
- (2016) Ingrid A. Mayer et al. Annual Review of Medicine
- Phase Ib trial of the PI3K/mTOR inhibitor voxtalisib (SAR245409) in combination with chemoimmunotherapy in patients with relapsed or refractory B-cell malignancies
- (2016) Farrukh T. Awan et al. BRITISH JOURNAL OF HAEMATOLOGY
- Phase I Study of Apitolisib (GDC-0980), Dual Phosphatidylinositol-3-Kinase and Mammalian Target of Rapamycin Kinase Inhibitor, in Patients with Advanced Solid Tumors
- (2016) S. O. Dolly et al. CLINICAL CANCER RESEARCH
- Randomized Open-Label Phase II Trial of Apitolisib (GDC-0980), a Novel Inhibitor of the PI3K/Mammalian Target of Rapamycin Pathway, Versus Everolimus in Patients With Metastatic Renal Cell Carcinoma
- (2016) Thomas Powles et al. JOURNAL OF CLINICAL ONCOLOGY
- MR spectroscopy for in vivo assessment of the oncometabolite 2-hydroxyglutarate and its effects on cellular metabolism in human brain gliomas at 9.4T
- (2016) Sotirios Bisdas et al. JOURNAL OF MAGNETIC RESONANCE IMAGING
- Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla
- (2016) Gaurav Verma et al. Journal of Translational Medicine
- In-VivoProton Magnetic Resonance Spectroscopy of 2-Hydroxyglutarate in Isocitrate Dehydrogenase-Mutated Gliomas: A Technical Review for Neuroradiologists
- (2016) Hyeonjin Kim et al. KOREAN JOURNAL OF RADIOLOGY
- Interrogating Metabolism in Brain Cancer
- (2016) Travis C. Salzillo et al. Magnetic Resonance Imaging Clinics of North America
- Multiparametric Imaging Analysis
- (2016) O. Rapalino et al. Magnetic Resonance Imaging Clinics of North America
- In vivo detection of 2-hydroxyglutarate in brain tumors by optimized point-resolved spectroscopy (PRESS) at 7T
- (2016) Sandeep K. Ganji et al. MAGNETIC RESONANCE IN MEDICINE
- MR Studies of Glioblastoma Models Treated with Dual PI3K/mTOR Inhibitor and Temozolomide:Metabolic Changes Are Associated with Enhanced Survival
- (2016) M. Radoul et al. MOLECULAR CANCER THERAPEUTICS
- Optimal differentiation of high- and low-grade glioma and metastasis: a meta-analysis of perfusion, diffusion, and spectroscopy metrics
- (2016) Jurgita Usinskiene et al. NEURORADIOLOGY
- Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma
- (2016) Jan C. Buckner et al. NEW ENGLAND JOURNAL OF MEDICINE
- Mutant IDH1 expression is associated with down-regulation of monocarboxylate transporters
- (2016) Pavithra Viswanath et al. Oncotarget
- Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells
- (2016) Pavithra Viswanath et al. Frontiers in Oncology
- Treatment Strategies for Low-Grade Glioma in Adults
- (2016) Nancy Ann Oberheim Bush et al. Journal of Oncology Practice
- 2-Hydoxyglutarate:D/Riving Pathology in gLiomaS
- (2015) Daniel R. Wahl et al. BRAIN PATHOLOGY
- IDH1 Mutation Induces Reprogramming of Pyruvate Metabolism
- (2015) J. L. Izquierdo-Garcia et al. CANCER RESEARCH
- Noninvasive Quantification of 2-Hydroxyglutarate in Human Gliomas with IDH1 and IDH2 Mutations
- (2015) U. E. Emir et al. CANCER RESEARCH
- Signaling through the Phosphatidylinositol 3-Kinase (PI3K)/Mammalian Target of Rapamycin (mTOR) Axis Is Responsible for Aerobic Glycolysis mediated by Glucose Transporter in Epidermal Growth Factor Receptor (EGFR)-mutated Lung Adenocarcinoma
- (2015) Hideki Makinoshima et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- Insulator dysfunction and oncogene activation in IDH mutant gliomas
- (2015) William A. Flavahan et al. NATURE
- Phase I dose-escalation study of the PI3K/mTOR inhibitor voxtalisib (SAR245409, XL765) plus temozolomide with or without radiotherapy in patients with high-grade glioma
- (2015) Patrick Y. Wen et al. NEURO-ONCOLOGY
- Comprehensive, Integrative Genomic Analysis of Diffuse Lower-Grade Gliomas
- (2015) NEW ENGLAND JOURNAL OF MEDICINE
- Dual PI3K/mTOR inhibitor, XL765 (SAR245409), shows superior effects to sole PI3K [XL147 (SAR245408)] or mTOR [rapamycin] inhibition in prostate cancer cell models
- (2015) Giovanni Luca Gravina et al. TUMOR BIOLOGY
- Metabolic Reprogramming in Mutant IDH1 Glioma Cells
- (2015) Jose L. Izquierdo-Garcia et al. PLoS One
- Epidemiologic and Molecular Prognostic Review of Glioblastoma
- (2014) J. P. Thakkar et al. CANCER EPIDEMIOLOGY BIOMARKERS & PREVENTION
- Phase I Safety, Pharmacokinetic, and Pharmacodynamic Study of SAR245409 (XL765), a Novel, Orally Administered PI3K/mTOR Inhibitor in Patients with Advanced Solid Tumors
- (2014) K. P. Papadopoulos et al. CLINICAL CANCER RESEARCH
- Targetable Signaling Pathway Mutations Are Associated with Malignant Phenotype in IDH-Mutant Gliomas
- (2014) H. Wakimoto et al. CLINICAL CANCER RESEARCH
- The mTORC1/S6K1 Pathway Regulates Glutamine Metabolism through the eIF4B-Dependent Control of c-Myc Translation
- (2014) Alfredo Csibi et al. CURRENT BIOLOGY
- The role of imaging in the management of progressive glioblastoma
- (2014) Timothy Charles Ryken et al. JOURNAL OF NEURO-ONCOLOGY
- Characterization of the Activity of the PI3K/mTOR Inhibitor XL765 (SAR245409) in Tumor Models with Diverse Genetic Alterations Affecting the PI3K Pathway
- (2014) P. Yu et al. MOLECULAR CANCER THERAPEUTICS
- Suppression of Feedback Loops Mediated by PI3K/mTOR Induces Multiple Overactivation of Compensatory Pathways: An Unintended Consequence Leading to Drug Resistance
- (2014) E. Rozengurt et al. MOLECULAR CANCER THERAPEUTICS
- Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation
- (2014) Jinlong Shi et al. TUMOR BIOLOGY
- Targeting PI3K/Akt/mTOR Signaling in Cancer
- (2014) Camillo Porta et al. Frontiers in Oncology
- Oncometabolites: linking altered metabolism with cancer
- (2013) Ming Yang et al. JOURNAL OF CLINICAL INVESTIGATION
- Lactate dehydrogenase A silencing in IDH mutant gliomas
- (2013) Charles Chesnelong et al. NEURO-ONCOLOGY
- Mutational Analysis Reveals the Origin and Therapy-Driven Evolution of Recurrent Glioma
- (2013) B. E. Johnson et al. SCIENCE
- Non-invasive in vivo assessment of IDH1 mutational status in glioma
- (2013) Myriam M. Chaumeil et al. Nature Communications
- Phase II study of Gleevec plus hydroxyurea in adults with progressive or recurrent low-grade glioma
- (2012) David A. Reardon et al. CANCER
- mTOR Signaling in Growth Control and Disease
- (2012) Mathieu Laplante et al. CELL
- Potential of MR spectroscopy for assessment of glioma grading
- (2012) Martin Bulik et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- 2-hydroxyglutarate detection by magnetic resonance spectroscopy in IDH-mutated patients with gliomas
- (2012) Changho Choi et al. NATURE MEDICINE
- Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation
- (2012) Sichen Li et al. NEURO-ONCOLOGY
- Neurocognitive functioning in adult WHO grade II gliomas: impact of old and new treatment modalities
- (2012) M. Klein NEURO-ONCOLOGY
- Detection of 2-Hydroxyglutarate in IDH-Mutated Glioma Patients by In Vivo Spectral-Editing and 2D Correlation Magnetic Resonance Spectroscopy
- (2012) O. C. Andronesi et al. Science Translational Medicine
- Signaling in Control of Cell Growth and Metabolism
- (2012) P. S. Ward et al. Cold Spring Harbor Perspectives in Biology
- Oncometabolite 2-Hydroxyglutarate Is a Competitive Inhibitor of α-Ketoglutarate-Dependent Dioxygenases
- (2011) Wei Xu et al. CANCER CELL
- Molecular subclassification of diffuse gliomas: Seeing order in the chaos
- (2011) Jason T. Huse et al. GLIA
- Non-invasive detection of 2-hydroxyglutarate and other metabolites in IDH1 mutant glioma patients using magnetic resonance spectroscopy
- (2011) Whitney B. Pope et al. JOURNAL OF NEURO-ONCOLOGY
- GDC-0980 Is a Novel Class I PI3K/mTOR Kinase Inhibitor with Robust Activity in Cancer Models Driven by the PI3K Pathway
- (2011) J. J. Wallin et al. MOLECULAR CANCER THERAPEUTICS
- Metabolism unhinged: IDH mutations in cancer
- (2011) John R Prensner et al. NATURE MEDICINE
- An in vivo patient-derived model of endogenous IDH1-mutant glioma
- (2011) H. A. Luchman et al. NEURO-ONCOLOGY
- Reduced phosphocholine and hyperpolarized lactate provide magnetic resonance biomarkers of PI3K/Akt/mTOR inhibition in glioblastoma
- (2011) H. S. Venkatesh et al. NEURO-ONCOLOGY
- Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide
- (2011) G. Prasad et al. NEURO-ONCOLOGY
- Molecular diagnostics of gliomas: the clinical perspective
- (2010) Ghazaleh Tabatabai et al. ACTA NEUROPATHOLOGICA
- The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate
- (2010) Patrick S. Ward et al. CANCER CELL
- The PI3K Pathway As Drug Target in Human Cancer
- (2010) Kevin D. Courtney et al. JOURNAL OF CLINICAL ONCOLOGY
- Imaging of Brain Tumors: MR Spectroscopy and Metabolic Imaging
- (2010) Alena Horská et al. NEUROIMAGING CLINICS OF NORTH AMERICA
- icoshift: A versatile tool for the rapid alignment of 1D NMR spectra
- (2009) F. Savorani et al. JOURNAL OF MAGNETIC RESONANCE
- Activation of PI3K/mTOR pathway occurs in most adult low-grade gliomas and predicts patient survival
- (2009) Sean M. McBride et al. JOURNAL OF NEURO-ONCOLOGY
- Cognitive and radiological effects of radiotherapy in patients with low-grade glioma: long-term follow-up
- (2009) Linda Douw et al. LANCET NEUROLOGY
- IDH1andIDH2Mutations in Gliomas
- (2009) Hai Yan et al. NEW ENGLAND JOURNAL OF MEDICINE
- NVP-BEZ235, a Dual PI3K/mTOR Inhibitor, Prevents PI3K Signaling and Inhibits the Growth of Cancer Cells with Activating PI3K Mutations
- (2008) V. Serra et al. CANCER RESEARCH
- Comprehensive genomic characterization defines human glioblastoma genes and core pathways
- (2008) Roger McLendon et al. NATURE
Publish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn MoreAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started